Genotoxicity of the neurotransmitter dopamine in vitro

Toxicology in Vitro

Volumn 23, Issue 4, 2009, Pages 640-646

  Stopper, Helga ^a   Schupp, Nicole ^a   Fazeli, Gholamreza ^a   Dietel, Barbara ^a   Queisser, Nina ^a   Walitza, Susanne ^a,b   Gerlach, Manfred ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Dopamine; Genotoxicity; Micronuclei; Oxidative stress

Indexed keywords

DIMETHYLTHIOUREA; DOPAMINE; DOPAMINE 2 RECEPTOR; HYDROGEN PEROXIDE; NOMIFENSINE; REACTIVE OXYGEN METABOLITE; SULPIRIDE; TEMPOL; VANOXERINE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRAIN; CELL STRAIN HL 60; COMET ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; LYMPHOBLASTOID CELL; MICRONUCLEUS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELLS, CULTURED; DOPAMINE; HUMANS; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; NOMIFENSINE; OXIDATIVE STRESS; PARKINSON DISEASE; PIPERAZINES; RATS; SULPIRIDE;

RATTUS;

EID: 67349280872     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.03.001     Document Type: Article

References (27)

1. Basma A.N., Heikkila R.E., Nicklas W.J., Giovanni A., and Geller H.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A. Journal of Neurochemistry 55 (1990) 870-877
2. Bolan E.A., Kivell B., Jaligam V., Oz M., Jayanthi L.D., Han Y., Sen N., Urizar E., Gomes I., Devi L.A., Ramamoorthy S., Javitch J.A., Zapata A., and Shippenberg T.S. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Molecular Pharmacology 71 (2007) 1222-1232
3. Bouzyk E., Gradzka I., Iwaneńko T., Kruszewski M., Sochanowicz B., and Szumiel I. The response of L5178Y lymphoma sublines to oxidative stress: antioxidant defence, iron content and nuclear translocation of the p65 subunit of NF-kappaB. Acta Biochimica Polonica 47 (2000) 881-888
4. Brink A., Schulz B., Stopper H., and Lutz W.K. Biological significance of DNA adducts investigated by simultaneous analysis of different endpoints of genotoxicity in L5178Y mouse lymphoma cells treated with methyl methanesulfonate. Mutation Research 625 (2007) 94-101
5. Chalimoniuk M., Stepień A., and Strosznajder J.B. Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clinical Neuropharmacology 27 (2004) 223-229
6. Chiasson K., Daoust B., Levesque D., and Martinoli M.G. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. Neurotoxicity Research 10 (2006) 31-42
7. Doggrell S.A. The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Expert Opinion on Investigational Drugs 11 (2002) 631-644
8. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacology and Therapeutics 91 (2001) 35-62
9. Junn E., and Mouradian M.M. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. Journal of Neurochemistry 78 (2001) 374-383
10. Kimmel H.L., Joyce A.R., Carroll F.I., and Kuhar M.J. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. Journal of Pharmacology and Experimental Therapeutics 298 (2001) 129-140
11. Lévay G., and Bodell W.J. Detection of dopamine-DNA adducts: potential role in Parkinson's disease. Carcinogenesis 14 (1993) 1241-1245
12. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nature Reviews Neuroscience 3 (2002) 932-942
13. McGregor D.B., Riach C.G., Brown A., Edwards I., Reynolds D., West K., and Willington S. Reactivity of catecholamines and related substances in the mouse lymphoma L5178Y cell assay for mutagens. Environmental and Molecular Mutagenesis 11 (1988) 523-544
14. Mehler-Wex C., Riederer P., and Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotoxicity Research 10 (2006) 167-179
15. Migliore L., Petrozzi L., Lucetti C., Gambaccini G., Bernardini S., Scarpato R., Trippi F., Barale R., Frenzilli G., Rodilla V., and Bonuccelli U. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
16. Moldeus P., Nordenskjold M., Bolcsfoldi G., Eiche A., Haglund U., and Lambert B. Genetic toxicity of dopamine. Mutation Research 124 (1983) 9-24
17. Petrozzi L., Lucetti C., Scarpato R., Gambaccini G., Trippi F., Bernardini S., Del Dotto P., Migliore L., and Bonuccelli U. Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. Neurological Sciences 23 2 (2002) S97-S98
18. Rajda C., Dibó G., Vécsei L., and Bergquist J. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients. Neuroimmunomodulation 12 (2005) 81-84
19. Riederer P., Gerlach M., Müller T., and Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism and Related Disorders 13 (2007) 466-479
20. Stern J.M., Chen J., Silver R.B., Poppas D.P., Vaughan Jr. E.D., and Felsen D. Effect of UUO on D1aR expression reveals a link among dopamine, transforming growth factor-beta, and nitric oxide. American Journal of Physiology - Renal Physiology 286 (2004) F509-F515
21. Stokes A.H., Brown B.G., Lee C.K., Doolittle D.J., and Vrana K.E. Tyrosinase enhances the covalent modification of DNA by dopamine. Molecular Brain Research 42 (1996) 167-170
22. 2 produced by monoamine oxidase. Kidney International 59 (2001) 76-86
23. Youdim M.B. Modulation of monoamine oxidase a activity in PC12 cells by steroids. European Journal of Pharmacology 192 (1991) 201-202
24. Younes-Mhenni S., Frih-Ayed M., Kerkeni A., Bost M., and Chazot G. Peripheral blood markers of oxidative stress in Parkinson's disease. European Neurology 58 (2007) 78-83
25. Weisler R.H. Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opinion on Emerging Drugs 12 (2007) 423-434
26. Zachor D.A., Moore J.F., Brezausek C., Theibert A., and Percy A.K. Cocaine inhibits NGF-induced PC12 cells differentiation through D(1)-type dopamine receptors. Brain Research 869 (2000) 85-97
27. Zeng C., Zhang M., Asico L.D., Eisner G.M., and Jose P.A. The dopaminergic system in hypertension. Clinical Science 112 (2007) 583-597